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1. Introduction  
Myocarditis is defined as a disease characterized by myocardial inflammation associated 
with myocyte necrosis. It can be caused by infections, autoimmune response primarily 
affecting the myocardium or by systemic autoimmune or inflammatory disorders (Aretz et 
al., 1986). Viral infections are the most frequent cause and account for the vast majority of 
cases in North America and Europe (Cooper, 2009). 
Cardiac symptoms that develop during myocarditis may follow after a delay of days to 
weeks from the beginning of the pathological process; they are quite unspecific and include 
fatigue, dyspnoea, palpitations, malaise and atypical chest discomfort. Even the clinical 
cardiac signs may be vague in many patients and generally include cardiac murmurs, gallop 
rhythms and other signs of heart failure and sometimes pericardial rubs when the 
pericardium is also involved in the inflammatory process. Myocarditis is often associated 
with various types of ECG abnormalities (including bundle branch blocks, Q waves 
resembling those related to myocardial infarction, repolarization abnormalities and QRS 
prolongation) and rhythm disturbance such as atrio-ventricular blocks, supraventricular 
tachycardias and ventricular ectopies and tachycardias. Echocardiography may reveal overt 
systolic dysfunction or a reduction of peak systolic velocities at TDI; moreover, regional wall 
motion abnormalities and diastolic dysfunction may be found (Cooper, 2009; Feldman et al. 
2000). Therefore, this disease should always be considered in patients who present with 
rapidly progressive cardiomyopathy, chest pain with ECG anomalies that mimic an acute 
coronary syndrome but with normal coronary arteries or idiopathic ventricular arrhythmias. 
Furthermore, in young people myocarditis may be frequently responsible for sudden 
cardiac death, particularly after strenuous physical exertion (Doolan et al., 2004; Corrado D 
et al. 2001). With this regard it should be highlighted that the recognition of myocarditis in 
patients presenting with aborted sudden death or major ventricular arrhythmias is actually 
challenging in everyday clinical practice, as the diagnosis may be difficult and may require 
the use of invasive procedures. Nevertheless, the detection of myocarditis in patients 
presenting with ventricular arrhythmias may have a pivotal importance, because the 
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identification of myocarditis as the substrate of arrhythmias is actually important for 
targeting therapies. 
In the last decades the development of new diagnostic techniques, in particular cardiac 
magnetic resonance, has led to an increased recognition of myocarditis as a cause of 
ventricular arrhythmias. However endomyocardial biopsy still represents the gold standard 
for the diagnosis of myocarditis. The main criticism against a wider use of endomyocardial 
biopsy in the diagnostic approach to patients with ventricular arrhythmias is represented by 
the possible sampling error in the presence of a focal myocarditis. We recently demonstrated 
that three dimensional electroanatomical mapping (3D-EAM) may guide endomyocardial 
biopsy identifying the segments of ventricular wall presenting an abnormal voltage, thus 
reducing sampling error and increasing sensitivity of biopsy. The systematic association of 
endomyocardial biopsy with electroanatomical mapping represents a significant 
improvement of the diagnostic tools available to identify the substrate of ventricular 
arrhythmias.  
In this chapter we describe the role of electroanatomical mapping-guided endomyocardial 
biopsy in the differential diagnosis of myocardial pathological substrates in patients with 
ventricular arrhythmias. We report the results of our group and other groups adopting this 
technique in different categories of patients, including subjects with a clinical diagnosis of 
arrhythmogenic right ventricular cardiomyopathy (ARVC), competitive athletes and 
patients with electrocardiographic diagnosis of Brugada syndrome.  
2. Myocarditis and ventricular arrhythmias 
Endomyocardial biopsy and autopsy findings have clearly demonstrated that myocarditis 
represents a frequent cause of life-threatening ventricular arrhythmias and sudden death. 
Post-mortem studies suggest that myocarditis is a major cause of sudden, unexpected death 
in adults less than 40 years of age (accounting for approximately 20% of cases - Fabre & 
Sheppard, 2006; Doolan et al., 2004). Indeed myocarditis may frequently cause ventricular 
arrhythmias associated with systolic dysfunction of left or right ventricle or both. In both its 
acute and chronic phase myocarditis may be associated with severe arrhythmias that can 
significantly affect the natural course of the disease, as they can further contribute to the 
deterioration of cardiac systolic and diastolic function and can be the ultimate cause of death 
in these patients (Magnani et al. 2006; Zeppenfeld et al. 2007; Graner et al, 2007). 
Mechanisms of arrhythmogenesis in the context of myocarditis include myocyte necrosis, 
replacement fibrosis (favoring re-entry mechanism), proarrhythmic effects of cytokines and 
inflammatory mediators possibly through a modulation of ion channel function.  
In patients with chronic active myocarditis, the perpetuation of inflammation is often 
related to viral persistence or to autoimmune self-maintaining mechanisms, and 
replacement fibrosis seems to represent a major arrhythmogenic substrate in this case, 
together with the permanence of an inflammatory milieu surrounding myocardiocytes. 
Moreover it has been demonstrated that enteroviral persistence perpetrates myocardial 
damage even in the absence of overt myocardial inflammation, through the release of 
proteases capable of cleaving dystrophin (Andreoletti et al., 2007). This in turns causes 
cytoskeleletal anomalies that can affect myocyte mechanical and even electric properties and 
finally lead to myocyte death, possibly contributing to arrhythmogenesis. 
Myocarditis may be the cause of ventricular arrhythmias even in subjects with no previous 
symptoms or presenting with an apparently normal heart or minimal electrocardiographic 
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and cardiac structural abnormalities (Theleman et al., 2001; Friedman et al., 1994). Subtle 
abnormalities not detectable by first-line examinations such as echocardiography may be 
present in patients with myocarditis presenting with ventricular arrhythmias. Other 
imaging modalities such as cardiac magnetic resonance (CMR) and even ventricular 
angiography are generally needed to detect these abnormalities. In a study published in 
2001 we found small aneurysms at ventricular angiography in patients with apparently 
idiopathic major ventricular arrhythmias; it should be underlined that all the patients 
enrolled in this study were also submitted to CMR that failed to detect microaneurysms in 
most patients (It is possible that currently used cine-sequences for functional analysis of 
both ventricles may enhance the diagnostic performance of CMR even in this setting). 
Histological examination of myocardial samples drawn from areas surrounding the 
aneurysms revealed the presence of active lymphocytic myocarditis with intense 
myocytolisis. Notably, no patient suffered from cardiac sudden death or malignant 
ventricular arrhythmias during a 1-year follow-up and sequential Holter recording showed 
progressive reduction of the arrhythmic burden. Furthermore neither heart failure episodes 
nor decrease of LV function were reported in the study population (Chimenti et al., 2001). 
Under this respect it should be noticed that inflammatory microaneurysms were also found 
in experimental animal models of myocarditis, namely in hamster and mice which survived 
to acute viral myocarditis, and they seem to cause electroanatomical abnormalities that are 
associated with development of severe ventricular arrhythmias; interestingly, in the 
inoculated animals the prognosis associated with the development of microaneurysms in 
the setting of experimental viral myocarditis was good with a survival similar to normal 
animals who had no aneurysms (Hoschino et al., 1984; Matsumori et al 1983). 
Myocarditis may selectively affect the right ventricle causing structural abnormalities, 
including microaneurysms, and arrhythmic manifestations typical of arrhythmogenic right 
ventricular cardiomyopathy. In fact myocardial inflammatory infiltrates associated with 
myocyte necrosis and replacement fibrosis, may lead to functional and structural changes of 
right ventricular myocardium resembling those produced by fibrofatty replacement, and 
representing the substrate of abnormal voltage map and ventricular arrhythmias (Hoffmann 
et al, 1993; Pieroni et al., 2009). Namely, our group demonstrated that biopsy-proven 
myocarditis is present in up to 50% of patients fulfilling current diagnostic criteria of 
arrhythmogenic right ventricular cardiomyopathy at non-invasive evaluation (including 
cardiac magnetic resonance), moreover myocarditis was associated to the presence of low-
voltage areas, as detected by 3D electro-anatomic mapping (Pieroni et al., 2009). 
Consistently it has been recently reported that also right ventricular sarcoidosis may mimic 
electroanatomic mapping features and arrhythmic presentation of arrhythmogenic right 
ventricular cardiomyopathy (Ott et al., 2003; Koplan et al. 2006; Vaisawala et al., 2009). 
Myocarditis represents a frequent cause of ventricular arrhythmias also in competitive 
athletes and its recognition and differential diagnosis with other cardiomyopathies with 
different prognosis may have important implications for sport eligibility (Basso C et al., 
2007). In fact, a recent study by our group demonstrated the presence of myocarditis, 
diagnosed by endomyocardial biopsy, in most elite athletes presenting with major 
arrhythmias and apparently normal heart. Moreover it should be emphasized that according 
to current diagnostic recommendations (the 2nd consensus document on Brugada Syndrome 
underlined the need to exclude other pathological conditions), the presence of a myocarditis 
should be always excluded in patients with electrocardiographic features leading to the 
diagnosis of Brugada syndrome. Among the pathologic conditions that can lead to a 
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Brugada-like phenotype, myocarditis of the right ventricle is one of the most frequently 
found when patients with Brugada syndrome are submitted to an extensive invasive and 
non-invasive evaluation (Frustaci et al., 2005; Okubo et al., 2010). In facts, a study on 18 
patients with Brugada Syndrome (diagnosed according to the consensus criteria) presenting 
with sustained ventricular arrhythmias or syncope, revealed the presence of biopsy-proven 
myocarditis in most patients (Frustaci el al., 2005). The complex links between myocarditis 
and genetically determined arrhythmic disorders is further discussed below in this chapter. 
Various studies on experimental animal models contributed to demonstrate that both 
autoimmune and viral myocarditis may cause major ventricular arrhythmia. Studies on 
murine models of myocarditis demonstrated that persistence of inflammation after the acute 
phase is associated with electrical abnormalities associated with ventricular arrhythmias; 
interestingly, a close correlation between the location of inflammatory burden (associated 
with myocyte necrosis), the reported electric abnormalities and the site of origin of 
arrhythmias was found (Kishimoto et al., 1983; Hoshino et al., 1982;). The major mechanisms 
involved in the genesis of arrhythmias seems to be the formation of micro-reentry circuits, 
favored by myocyte injury and replacement fibrosis, and triggered activity mainly due to 
the pro-arrhythmic effects of cytokines. Moreover it was reported that the environment 
surrounding myocytes could influence the electrophysiological properties of the 
myocardium, this phenomenon is known as electrical remodeling. As previously pointed 
out the inflammatory process of the myocardium may itself be arrhythmogenic, nonetheless 
the change in the electrophysiological properties of the myocardiocytes seems also play a 
role in causing the arrhythmias. Changes in expression of surface ion channels, as assessed 
by quantitative determination of mRNA expression, have been demonstrated in animal 
experimental models of both viral and autoimmune myocarditis; these changes, affecting 
mainly potassium and calcium channels, causes modification of the ventricular effective 
refractory period, which appear to be longer in myocarditis, an increase in monofasic action 
potential duration of the ventricular myocardium and an augment of ventricular 
vulnerability that ultimately favors the genesis of ventricular arrhythmias (Saito et al., 2006). 
Interestingly, some data suggests that these changes may be transient and can reverse after 
the healing of the inflammatory process. Altogether, these data further support the 
hypothesis that active inflammation represents a major substrate of ventricular arrhythmias 
and suggests that pro-arrhythmic changes of myocardial electrical properties caused by the 
inflammation might be, completely or partially, reversed after the healing of the 
inflammatory process. 
2.1 Myocarditis and sudden arrhythmic death 
In the last decades myocarditis has emerged as an important cause of sudden arrhythmic 
death also in patients with a structurally and functionally normal heart. The most striking 
evidence that myocarditis may be the substrate of sudden arrhythmic death is represented 
by a study on Air Force recruits victims of cardiac sudden death in which myocarditis was 
recognized as the cause of death in 40% of cases (Phillips et al., 1986) 
Although no data on cardiac function before death were available in the study, the 
percentage of cases in which myocarditis was observed at necropsy studies indicates the 
high arrhythmic risk related to myocarditis. In more recent studies the percentage of 
myocarditis detected at necropsy in subjects with sudden arrhythmic death and an 
apparently normal heart ranged from 5 to 12% (Doolan et al., 2004; Thelemann et al., 2001).  
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In a study performed in our Institution in 1994 seventeen young patients (10 males and 7 
females, aged 14 to 38 years, mean 26.4) without overt organic heart disease, who had been 
resuscitated from sudden cardiac arrest were submitted to noninvasive 
(electrocardiography, 2D-echocardiography, and magnetic resonance imaging) and invasive 
(coronary angiography with ergonovine testing, electrophysiologic study and biventricular 
angiography and endomyocardial biopsy) cardiac studies. Six to 8 biopsy fragments per 
patient were processed for histology and electron microscopy and read by a pathologist 
blinded to clinical data. Two groups of patients were distinguished by invasive and 
noninvasive examinations: Group 1 consisted of 9 patients with entirely normal parameters; 
Group 2 consisted of 8 patients with structural, nonspecific cardiac abnormalities. In this 
latter group, mild to moderate dilatation and hypokinesia of the left ventricle were 
documented in 4 patients, concentric left ventricular hypertrophy was seen in three patients, 
and RV dysfunction was noted in 1 patient. Histologic examination was abnormal in all 
patients and revealed specific lesions in 65% of them; in particular an active myocarditis was 
diagnosed in 6 out of 9 patients in the Group 1. In these 6 patients immunosuppressive 
therapy (steroids plus azathioprine) administered on top of conventional antiarrhthmic 
treatment led to dispappearance of ventricular arrhythmias and healing of myocardial 
inflammation at follow-up endomyocardial biopsies (Frustaci et al., 1994) Similarly in a 
study from the Padua group in a series of 273 sudden cardiac deaths victims, 76 cases (28%) 
presented a macroscopically normal heart: of these 60 (79%) had abnormal histology with a 
36% of cases of active myocarditis (Corrado et al., 2001). These data suggest that myocarditis 
represents an important, frequently unrecognized and underestimated, cause of sudden 
arrhythmic death. Moreover these studies dramatically demonstrate that sudden arrhythmic 
death may represent the very first clinical manifestation of myocarditis. Accordingly the 
consensus document based on the two main registries on sudden arrhythmic death (the 
UCARE, Unexplained Cardiac Arrest Registry of Europe and the IVF-US, Idiopathic 
Ventricular Fibrillation Registry of United States) includes myocarditis among the 
subclinical disorders that may cause sudden death (UCARE, 1997). 
It should be also emphasized that myocarditis is a cause of sudden arrhythmic death even in 
competitive athletes, more frequently exposed to viral infections of upper airways. With this 
regard it has been claimed but never conclusively demonstrated that exercise in the context 
of an active myocarditis may represent a further arrhythmic trigger. 
2.1.1 Myocarditis and genetically determined arrhythmic syndromes 
In the last decades several studies suggested a role for myocardial inflammation in the 
pathogenesis of different genetically determined arrhythmic syndromes and 
cardiomyopathies. In the presence of gene mutations leading to abnormal structure and/or 
function of structural and functional proteins, myocardial inflammation may act as a 
mechanism of myocardial damage, amplificating the dysfunction related to the genetic 
abnormalities, or rather as trigger of specific clinical manifestations, such as arrhythmias, 
occurring later in the natural history of the disease. Myocardial inflammation has been 
observed in necropsy and endomyocardial biopsy studies in genetically determined 
myocardial disorders, including ARVC, Brugada syndrome and hypertrophic 
cardiomyopathy. 
In ARVC myocardial inflammation may be seen in up to 75% of hearts at autopsy, and 
probably it plays a role in triggering ventricular tachyarrhythmias (Thiene et al., 2001). 
Nobody knows whether inflammation is a reactive phenomenon to cell death, or whether it 
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is the consequence of an infection or immune mechanism. Viruses have been detected in the 
myocardium of some ARVC patients and have been claimed to support an infective etiology 
of the disease (Bowles et al., 2002). Others say that the viruses are innocent bystanders or 
that spontaneous cell degeneration may serve as a milieu favoring viral settlement in the 
myocardium (Calabrese et al., 2006). In addition we and others demonstrated that 
myocarditis may present with clinical and arrhythmic features and structural right 
ventricular abnormalities resemblig those observed in ARVC. (Chimenti et al., 2004; Pieroni 
et al., 2009). 
With regard to Brugada syndrome we studied 18 consecutive patients with clinical 
phenotype of Brugada syndrome and normal cardiac structure and function on noninvasive 
examinations. Clinical presentation was ventricular fibrillation in 7 patients, sustained 
polymorphic ventricular tachycardia in 7, and syncope in 4. All patients underwent cardiac 
catheterization, coronary and ventricular angiography, biventricular endomyocardial 
biopsy, and DNA screening of the SCN5A gene. Biopsy samples were processed for 
histology, electron microscopy, and molecular screening for viral genomes. In 14 patients 
histology showed a prevalent or localized right ventricular myocarditis, arrhythmogenic 
right ventricular cardiomyopathy in 1 patient and cardiomyopathic changes in 3. In the latter 
4 patients genetic studies identified SCN5A gene mutations causing in vitro abnormal 
function of mutant proteins. In these patients, myocyte cytoplasm degeneration and a 
significant increase of apoptotic myocytes in right and left ventricle versus normal controls 
were observed (Frustaci et al., 2005). This study highlighted the complexities between the 
clinical manifestations of Brugada syndrome, the presence of SCN5A mutations, and the 
presence of structural heart disease and provided striking new evidence implicating 
myocarditis in the transient development of Brugada-like ECG abnormalities and 
arrhythmias.  
However it still remains unclear whether myocardial inflammation may be part of the 
structural changes following an abnormal ion channel function, or rather right ventricular 
myocarditis may mimic ECG and arrhythmic features of Brugada syndrome. Further studies 
combining genetic analysis and accurate pathology studies are needed to clarify the complex 
menage a trois between abnormal gene function (whether affecting desmosomal or ion 
channel proteins), myocardial inflammation and inherited arrhythmic syndromes.  
Myocarditis has been also observed in patients with hypertrophic cardiomyopathy and 
severe arrhythimic manifestations, suggesting that inflammation may act as a trigger for 
life-threatening ventricular arrhythmias when affecting a myocardium already prone to 
electrical instability (Frustaci et al., 2007). Even in this context it is not clear whether 
myocardial inflammation was the result of a reactive process related to ischemic myocyte 
necrosis or rather a superimposed autoimmune or viral process. 
3. The diagnosis of myocarditis in patients with ventricular arrhythmias 
Myocardial inflammation represents a potent pro-arrhythmic substrate, myocarditis should 
always be taken into account when facing with ventricular arrhythmias. Furthermore the 
detection of myocarditis as the pathological substrate underlying ventricular arrhythmias 
may be crucial as the identification of myocarditis as the etiology of the arrhythmias is 
actually important for targeting therapies and may have implications even for patients’ 
relatives as discussed below in the chapter. In the last decades the development of new 
imaging techniques, in particular CMR, led to an increased recognition of myocarditis as a 
cause of ventricular arrhythmias.  
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3.1 Cardiac magnetic resonance 
Cardiac Magnetic resonance offers a combination of clarity of anatomical visualization, 
interobserver consistency and quantitative accuracy, even when evaluating the right 
ventricle, which enables to overcome the major pitfalls of echocardiography. Furthermore it 
is characterized by the unique feature of providing some degree of tissue characterization, 
thus allowing to obtain non-invasively information about the presence of necrosis, fibrosis 
and edema. Nonetheless CMR has some limitations due to the technical difficulty in 
obtaining good images in patients with arrhythmias that cause high variability of cardiac 
cycle length and also due to safety issues related to the presence of cardiac rhythm devices. 
Recently a panel of international experts on CMR has published a white paper in which 
imaging protocols and diagnostic criteria are defined that should be used in the setting of 
myocarditis. According to this consensus (Friedrich et al., 2009), a diagnosis of myocarditis 
can be set when at least two of the following features are present: one area of non-ischemic 
(i.e. sparing of sub-endocardial layers of the myocardium and/or distribution of areas not 
consistent with coronary perfusion territories) late gadolinium enhancement (consistent 
with myocyte injury and scarring), global or regional signal increase in T2-weighted images 
(indicative of tissue oedema) and global early gadolinium enhancement  (consistent with 
hyperemia) (Figure 1). 
 
 
Fig. 1. Diagnosis of myocarditis through CMR in a patient with sustained ventricular 
arrhythmias. Evidence of spotty areas of sub-epicardial and midwall late enhancement (non-
ischemic pattern) in the lateral wall (A), associated with areas of edema (high signal 
intensity on T2-weighted images) in the same location (B). The presence of both late 
enhancement and edema fulfils the criteria proposed by the consensus document. 
In many studies CMR has demonstrated to be useful for the assessment of the presence of 
pathological substrates underlying ventricular arrhythmias. Its use allowed to detect the 
presence of structural cardiomyopathies including myocarditis (Ordovas et al. 2008) in up to 
30% of patients. Clinical studies specifically addressing the diagnostic yield of CMR in the 
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setting of myocarditis presenting with either arrhythmia or heart failure reported a 
sensitivity and specificity of more then up to 90% (Mahrholdt et al., 2004). Moreover, CMR 
was able to differentiate active from healing inflammation in patients presenting with 
chronic myocarditis. 
In particular, De Cobelli and colleagues studied patients presenting with chronic 
myocarditis assessed with EMB and CMR; they found areas of high signal intensity in T2-
weighted images in 36% of patients with histological evidence of active myocarditis, but not 
in patients with borderline myocarditis. They also found areas of late gadolinium 
enhancement in 84% and 44% of patients with active and borderline myocarditis, 
respectively. A midwall pattern of late enhancement was a frequent finding in patients with 
both active myocarditis and borderline myocarditis, whereas a subepicardial pattern was 
only observed in patients with histological evidence of active myocarditis (De Cobelli et al., 
2004). Taken together, these data support the need to include sequences for the detection of 
myocardial inflammation when CMR is performed in the non-invasive diagnostic work-up 
of patients presenting with ventricular arrhythmias (Figure 2). In addition CMR represents 
an important noninvasive tool in the follow-up of patients with a diagnosis of myocarditis. 
 
 
Fig. 2. CMR findings in a patient with chronic myocarditis presenting with ventricular 
arrhythmias. ECG shows repetitive polymorphic ventricular ectopic beats (A). CMR shows 
sub-epicardial late enhancement in the posterior and postero-lateral walls (B) and 
transmural edema in the same location (C). Histology shows the presence of active 
myocarditis (D).  
3.2 Endomyocardial biopsy 
Despite the improvement of imaging techniques, endomyocardial biopsy still represents the 
gold standard for the diagnosis of myocarditis as allow the recognition and the 
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characterization of the myocardial inflammatory process, the assessment of myocyte 
necrosis and fibrosis as well as the possible detection of viral genomes.  
A recent statement from AHA/ACC/ESC (Cooper et al., 2007) aimed to define the role of 
endomyocardial biopsy in the management of cardiovascular disease, identified 14 clinical 
scenarios in which the incremental diagnostic, prognostic and therapeutic value of 
endomyocardial biopsy could be estimated and compared with the procedural risks. 
According to this statement, in the absence of randomized clinical trials or multicenter 
studies, endomyocardial biopsy may be considered in the setting of unexplained ventricular 
arrhythmias (Clinical scenario 13) only in exceptional cases in which the perceived 
likelihood of meaningful prognostic and therapeutic benefit outweighs the procedural risks 
(Class of recommendation IIb, Level of evidence C). 
Nevertheless there is growing evidence that endomyocardial biopsy may be crucial to 
clarify the pathological substrate and therefore the cause of otherwise unexplained 
ventricular arrhythmias, with a possible impact on both treatment and prognosis as detailed 
further in this chapter. 
Accordingly a recent document from the Italian federation of Cardiology (Leone et al., 2009) 
suggested indications to endomyocardial biopsy different from the above-mentioned 
statement, in particular with regard to patients with ventricular arrhythmias. The authors 
graded clinical indications according to the following scheme:  
 Grade 1: there are no alternative tools to obtain a definite diagnosis and the clinical 
implications of diagnosis are certain. 
 Grade 2A: there are no alternative tools to obtain a definite diagnosis and the clinical 
implications of diagnosis are uncertain. 
 Grade 2B: there are no alternative tools to obtain a definite diagnosis but the diagnosis 
has scientific but no clinical implications. 
 Grade 3: there are alternative tools to obtain a definite diagnosis. 
According to this grading, taking into account the potential diagnostic usefulness of 
endomyocardial biopsy in different myocardial disorders, the authors identified several 
clinical scenarios. In the presence of sustained and/or life-threatening ventricular 
arrhythmias, when a myocarditis is suspected or is a possible diagnosis, the grade of 
recommendation to perform endomyocardial biopsy is 1. Similarly in the presence of AV 
blocks associated with a clinical context consistent with a diagnosis of myocarditis, 
recommendations are Grade 2A and 2B in the presence or in the absence of left ventricular 
dysfunction respectively. Therefore the Italian Federation of Cardiology document seems to 
more adequately address the diagnostic and therapeutic issues that are frequently faced by 
cardiologists in everyday clinical practice when dealing with patients with severe 
ventricular arrhythmias or atrioventricular conduction disturbances and no evidence of 
ischemic heart disease or overt valvular or myocardial disease. 
Both documents do also indicate how many samples are needed in different clinical 
conditions, how to handle and process myocardial samples, and which studies are necessary 
to obtain the desired diagnostic information. In the case of clinically suspected myocarditis 5 
to 10 samples must be obtained to perform histology and immunohistochemistry studies 
and molecular bioloy studies to detect the presence of viral genomes. Samples for molecular 
biology must be flash-frozen in liquid nitrogen and stored at -80°C. Endomyocardial biopsy 
should better not be performed in patients with clinically suspected myocarditis, if 
immunohistochemistry and virology studies are not available. 
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The main criticism against a wider use of endomyocardial biopsy in the diagnostic approach 
to patients with ventricular arrhythmias is represented by the possible sampling error in the 
presence of a focal myocarditis. In fact, as previously mentioned, the myocardial 
inflammation in patients presenting with arrhythmias may present a patchy distribution 
and therefore myocardial samples drawn from a same conventional site (the right side of 
interventriculrar septum or the left ventricular apex) may not include myocardial tissue 
involved by the inflammatory process. Increasing the number of samples obtained or 
arbitrarily changing the site of biopsy can in part minimize sampling error, but these tricks 
may increase the risks of the procedure. To overcome the sampling error and increase the 
diagnostic sensistivity of endomyocardial biopsy, we recently demonstrated that in patients 
presenting with ventricular arrhythmias, electroanatomical mapping may guide the 
execution endomyocardial biopsy identifying the segments of ventricular wall presenting an 
abnormal voltage, suggesting an abnormal histological substrate (Pieroni et al, 2009; Casella 
& Dello Russo, 2009). This technique represents an important innovation in the field of 
endomyocardial biopsy as reduces sampling error and increases the sensitivity of biopsy, 
thus possibly reducing the number of samples needed for a complete study of myocardial 
tissue and therefore reducing the risks of the procedure. 
3.3 Electroanatomic mapping 
Electroanatomic mapping allows operators to record intracardiac electrical activation in 
relation to anatomic location in a cardiac chamber of interest, even during arrhythmia 
mapping. Several 3D-EAM systems are currently available that accomplish these tasks. 
When applied properly, such technology allows one to accurately determine the location of 
arrhythmia origin, define cardiac chamber geometry in three dimensions, delineate areas of 
anatomic interest, and allow catheter manipulation and positioning without fluoroscopic 
guidance. These systems often simplify mapping efforts and can enhance procedural 
success, particularly in cases in which complex arrhythmias and unusual cardiac anatomy 
are encountered. 
The CARTO mapping system (Biosense, Diamond Bar, CA, USA) is a three-dimensional 
nonfluoroscopic mapping system that utilizes a low-level magnetic field (5 x 10-6 to 5 x 10-5 
Tesla) delivered from three separate coils in a locator pad beneath the patient. The magnetic 
field strength from each coil is detected by a location sensor embedded proximal to the tip of 
a specialized mapping catheter. The strength of each coil's magnetic field measured by the 
location sensor is inversely proportional to the distance between the sensor and coil. Hence, 
by integrating each coil's field strength and converting this measurement into a distance, the 
location sensor (and therefore, catheter tip location) can be triangulated in space. The 
mapping catheter has proximal and distal electrode pairs, and a tip electrode capable of 
radiofrequency energy delivery. This catheter can be moved along a chamber's surface to 
record local endocardial activation times for arrhythmia mapping, while simultaneously 
recording location points to generate 3D chamber geometry. Validation studies have shown 
CARTO to have substantial accuracy in navigating to single points, in returning to prior 
ablation sites, and in creating a desired length of ablation line. Electrograms recorded from 
the specialized mapping (NaviSTAR) catheter showed excellent correlation with recordings 
from standard EP catheters. Moreover human validation studies have shown a good level of 
spatial precision and accuracy, and realistic reconstruction of chamber geometry and 
electroanatomic activation during arrhythmia mapping. Nevertheless in our experience, the 
comparison between biplane right ventricular angiography and the 3D reconstruction 
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obtained by CARTO showed that small structures such as microaneurysms, can be missed 
by the mapping catheter and therefore are not properly visualized. These limitations would 
be partially overcome by importing CT and CMR images and merging them with 3D maps 
so that during mapping the catheter can be visualized inside the anatomical images.  
Similar to CARTO the NavX system is a mapping and 3D nonfluoroscopic intracardiac 
browsing system that can reconstruct in real time geometry as well as the electric activation 
of the heart chamber. NavX technology makes use of six surface patch electrodes that 
generate, once correctly positioned, an electric filed. Within this electric field it is possible to 
locate in real time the position of every electrophysiology catheter employed during the 
procedure, including the cardiac bioptome when electically connected to the mapping 
system. We tested both systems in guiding endomyocardial biopsy execution. Although a 
comparison between the systems exceeds the scopes of this chapter, CARTO system 
probably offers a more detailed reconstruction of the ventricular chambers, while NavX 
system has the advantage of direct real time visulization of the bioptome in the 3D map. In 
this chapter we will refer to the CARTO system as it was more frequently used in our and 
other studies. 
High-density mapping must be obtained in sinus rhythm (reference channel: QRS complex) 
by sampling at least 100 points in each chamber, uniformly distributed. The voltage maps 
are then edited setting the point density (fill threshold) at 15 mm and manually eliminating 
intracavitary points. According to current literature “electroanatomic scar” is defined as an 
area including at least 3 adjacent points with bipolar signal amplitude <0.5 mV; the 
reference value for normal endocardium is usually set at 1,5 mV. In the CARTO system the 
color display to identify normal and abnormal voltage myocardium ranges from red 
(electroanatomic scar tissue; amplitude <0.5 mV), to purple (electroanatomic normal tissue; 
amplitude ≥1.5 mV). Intermediate colors represent the electroanatomic border zone  
(amplitude >0.5 and <1.5 mV) (Figure 3). 
 
 
Fig. 3. Example of electroanatomic maps obtained with CARTO (A) and NavX (B) systems. 
For colours interpretation see text. 
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Adequate catheter contact should be confirmed by concordant catheter tip motion with the 
cardiac silhouettes on fluoroscopy and by adherence of voltage map to angiographic right 
ventricular shape. To avoid low voltage recordings due to poor contact, the following tools 
can be used: 1) the signal has to satisfy 3 stability criteria automatically detected by CARTO 
system in terms of cycle length, local activation time and beat-to-beat difference of the 
location of the catheter (<2%, <3 ms, and <4 mm, respectively); 2) both bipolar and unipolar 
signals are simultaneously acquired to confirm true catheter contact through the analysis of 
local electrogram (in particular the shape of the unipolar electrogram); 3) in the presence of a 
low voltage area, at least 3 additional points should be acquired in the same site to confirm 
the reproducibility of the voltage measurement. The anatomical distribution of the 
pathological areas is evaluated dividing the right ventricular voltage map into five 
segments: outflow tract, free (anterolateral) wall, inferior and posterior basal segments, 
apex, and interventricular septum. 
3.4 Electroanatomic mapping-guided endomyocardial biopsy 
The main limitation of endomyocardial biopsy to provide a specific diagnosis in patients 
with ventricular arrhythmias caused by focal myocardial diseases, (i.e. myocarditis or initial 
forms of arrhythmogenic right ventricular cardiomyopathy), is represented by the sampling 
error due to the lack of an effective guide in selecting ventricular areas where to perform 
biopsies. In the last years, after the development of 3D-EAM systems, we introduced a new 
technique for the execution of endomyocardial biopsies in patients with ventricular 
arrhythmias (Pieroni et al., 2009).  
3.4.1 Technique 
The new approach is aimed to perform endomyocardial biopsies in the ventricular segments 
presenting electrical abnormalities at electroanatomical mapping. When using the CARTO 
system, once the electroanatomical map is completed, the mapping catheter is placed in a 
region of interest of the ventricular wall and the preformed sheath is positioned closed to 
the catheter tip (Figure 4). Endomyocardial biopsy is then performed in the area with 
abnormal electrical properties as showed by the map. As previously mentioned, another 
approach we tested requires the electrical connection of the bioptome to the mapping 
system: the presence of the metallic jaws makes the bioptome similar to a mapping catheter 
and it is therefore visualized in the 3D electroanatomical map of the ventricle. In this case, 
the site of biopsy can be chosen “live”, directly mapping the ventricular wall with the 
bioptome (Figure 4). The latter technique can be adopted when using the NavX mapping 
system. With both systems we usually performed ventricular angiography before the 
execution of ventricular mapping, in order to improve the anatomical accuracy of the map, 
as angiography still represents the gold standard to detect wall motion abnormalities and 
small aneurysms of the right venticle. 
Although no data on specificity and sensitivity of 3D-EAM-guided vs. conventional 
technique are currently available in literature, it is reasonable that obtaining myocardial 
samples from areas of the ventricular wall presenting electrical abnormalities will probably 
reduce the sampling error and the need for multiple biopsies from the same patient (See 
below). Moreover the combination of 3D-EAM with other imaging tools such as cardiac MRI 
would further improve our ability to obtain samples from selected regions that present 
structural, functional and electrical abnormalities.  
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Fig. 4. 3D-EAM-guided EMB. With the CARTO system (A) the long sheath with the 
bioptome inside (arrow) is positioned near to the mapping catheter (arrowhead). With the 
NavX system (B) the bioptome tip (green point and arrow) can be directly visualized in the 
3D ventricular map. 
3.4.2 Safety 
The execution of endomyocardial biopsies drawing myocardial samples from non 
conventional sites, including the right ventricular free-wall and outflow tract do not increase 
the risks of the procedure. Since 2006 we perfomed 3D-EAM-guided endomyocardial biopsy 
in more than sixty patients with about 400 samples obtained. In order to evaluate the safety 
of this new approach we prospectively analysed the rate of major and minor complications 
through continuous ECG monitoring during the procedure, ECG and 2D-echocardiography 
at the end the procedure and after 3 and 6 hours. Major complications included pericardial 
tamponade with need for pericardiocentesis, hemo- and pneumopericardium, permanent 
atrioventricular block requiring permanent pacemaker implantation, myocardial infarction, 
transient cerebral ischemic attack and stroke, severe valvular damage, and death, whereas 
minor complications included transient chest pain, transient ECG abnormalities, transient 
arrhythmias, transient hypotension, and small pericardial effusions. The major complication 
rate was 0% and the minor complication rate was 4.5%: minor complications were 
represented by small pericardial effusions in 2 patients and chest pain in 1. These rates are 
in line with those observed in a recent large two-centers study including 755 procedures 
(right, left and biventricular endomyocardial biopsy) and reporting a major and minor 
complication rate of 0.82% and 5.1% respectively for right ventricular endomyocardial 
biopsy (Yilmaz et al., 2010). In literature another study in which 3D-EAM-guided 
endomyocardial biopsy was performed in 22 patients, reported a higher rate of major 
complications (1.1%) and minor complications (5.7%), thus suggesting that the expertise of 
the operators besides the clinical condition and the underlying disorder may influence the 
safety of the procedure (Avella et al., 2008). 
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4. Electroanatomic mapping-guided endomyocardial biopsy in patients with 
ventricular arrhythmias 
There is growing evidence that 3D-EAM-guided endomyocardial biopsy represent a new 
important tool to improve the diagnosis and the treatment of patients with arrhythmias, as 
well as the knowledge of the pathological substrates and mechanisms ubderlying 
arrhythmic syndromes. Since 2006 we performed 66 3D-EAM-guided endomyocardial 
biopsy procedures. In all cases the biopsies where drawn from the right ventricle, with 
biventricular mapping and 3D-EAM-guided biopsy being performed in 10 patients. 
Although data on a direct comparison between 3D-EAM-guide and conventional technique 
are not yet available, the 3D-EAM-guided approach seems to significantly improve the 
diagnostic sensitivity and specificity of endomyocardial biopsy. In fact, when applying 
immunohistochemistry and molecular biology techniques, a definite histologic diagnosis 
was obtained in all cases. The new technique was firstly adopted in a series of 30 patients 
with a noninvasive diagnosis of ARVC according to current diagnostic criteria (Pieroni et al., 
2009). Twenty-nine (97%) of 30 patients presented an abnormal voltage map. Histology and 
immunohistochemistry confirmed the diagnosis of ARVC in 15 patients, while showed an 
active myocarditis in the remaining 15 patients (Figure 5). Patients with ARVC were not 
distinguishable on the basis of clinical features, presence and severity of structural and 
functional right ventricular abnormalities and three-dimensional 3D-EAM findings. 
 
 
Fig. 5. 3D-EAM-guided EMB, in a patient with bigeminism due to ventricular ectopic beats 
with LBBB morphology and inferior axis (A). 3D-EAM shows low voltages in the outflow 
tract and free wall (B). Endomyocardial biopsies drawn from free wall (arrow) shows active 
myocarditis (C). 
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On the basis of clinical and histological features, a cardioverter defibrillator was implanted 
in 13 patients with biopsy-proven ARVC and in 1 patient only with myocarditis. At a mean 
follow-up of 21±8 months, 7 (47%) patients with ARVC experienced recurrence of 
symptomatic sustained ventricular arrhythmias with appropriate defibrillator intervention 
in all cases. All patients with myocarditis remained asymptomatic and free from arrhythmic 
events. Our study was the first to demonstrate that 3D-EAM-guided EMB may allow 
obtaining a differential diagnosis in patients with otherwise undistiguishable clinical, 
arrhythmic and imaging features. In addition our study clearly showed that patients with 
similar arrhythmic presentation may have a dramatically different prognosis in terms of 
arrhythmias’ recurrence according to the underlying disorders, as only 53% of biopsy-
proven ARVC patients remained free from arrhythmias at a mean follow-up of 21±8 months 
years, while no patients with biopsy-proven myocarditis experienced major arrhythmic 
events during the same time (Figure 6). 
 
 
Fig. 6. Kaplan-Meier analysis of arrhythmic event-free survival depending on the 
histological findings (Modified from Pieroni et al. 2009). 
In a more recent study (Pieroni et al unpublished data) we performed 3D-EAM-guided EMB 
in a series of elite competitive athletes presenting with sustained ventricular arrhythmias. 
We studied 13 consecutive competitive athletes with evidence of sustained ventricular 
arrhythmias within the previous six months on 12-lead ECG, 24-hour Holter ECG or ECG 
exercise testing and who were judged as having a structurally normal heart after a thorough 
non-invasive evaluation, including signal-averaged electrocardiogram, transthoracic 
echocardiogram and CMR. Depending on the presumed site of arrhythmias origin 
according to 12-lead ECG criteria, patients underwent right or left ventricular 3D-EAM and 
3D-EAM-guided endomyocardial biopsy. Twelve (92%) patients presented at least 1 low-
voltage region at 3D-EAM, while the histologic diagnosis was active myocarditis in 7 
patients, and of arrhythmogenic RV cardiomyopathy in 5. In one patient the histological 
evidence of contraction-band necrosis allowed to unmask caffeine and ephedrine abuse. 
The identification of the underlying histological substrate in patients with ventricular 
arrhythmias may be relevant also when radiofrequency catheter ablation (RFCA) is 
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considered as a possible therapeutic strategy. In fact there is growing evidence that in 
patients with ARVC, RFCA is effective in abolishing ventricular tachycardias, but the rate or 
recurrence of arrhthmias with the same or a different morphology may be very high even 
when an epicardial approach is adopted (Dalal et al., 2007). On the contrary several reports 
have demonstrated that RFCA may be effective in eliminating ventricular arrhythmias in 
myocardial inflammatory disorders, including Chagas cardiomyopathy and sarcoidosis 
(Sosa et al., 1999; Sarabanda et al., 2005; Jefic et al., 2009; Henz et al., 2009). Recent reports 
and also our experience suggest that endocardial ablation cannot be sufficient in some 
patients and a combined endo-epicardial approach is required for definitive results. (See 
below, Clinical implications of myocarditis diagnosis) 
5. Clinical implications of myocarditis diagnosis in patients with ventricular 
arrhythmias 
Despite the improvement of diagnostic techniques in defining the characteristics and the 
etiology of the inflammatory process and the more specific comprehension of the 
mechanisms leading to myocardial damage, a specific standardized treatment of 
myocarditis is not yet available. However in the last decades several studies and trials have 
clearly demonstrated that an etiologic definition of myocarditis based on the 
immunohistological evaluation of inflammation and proof of viral infection by PCR on 
biopsies is essential for targeting appropriate treatment strategies indicating that 
myocarditis patients may benefit from immunosuppression, provided that viral persistence 
is excluded, while patients with viral persistence fail to respond favourably or deteriorate by 
immunosuppression.  
Several studies have demonstrated the negative prognostic role of viral persistence. In a 
recent study Kuhl and colleagues analyzed 172 patients with dilated cardiomyopathy and 
biopsy-proven viral infection in endomyocardial biopsies. The authors reported a high 
prevalence of enteroviral and parvovirus B19 infection (32.6% and 36.6%, respectively) and 
found that viral persistence was associated with a progressive impairment of left ventricular 
ejection fraction, whereas spontaneous viral elimination was associated with a significant 
improvement in left ventricular function (Kuhl et al., 2005). 
Autoimmunity, on the other hand, may play an outstanding role in the progression of 
myocardial damage and persistence of symptoms, including ventricular arrhythmias. 
Notably, both acute viral infection and chronic viral persistence can induce autoimmunity 
by mechanisms not fully elucidated. Molecular mimicry has been suggested as one 
mechanism to explain chronic myocarditis (Caforio et al., 2002; Rose et al., 2006) and several 
cellular antigens have been identified to cross-react with viral antigens, thus providing 
possible targets in virus-induced myocarditis. Autoantibody production also may be caused 
by the initial myocyte damage by viral infection, releasing increased amounts of self-
antigens into the circulation. Autoantibodies against adrenergic and acetylcholine receptors 
contractile structures, extracellular matrix proteins, proteins involved in energy metabolism, 
calcium receptors and homeostasis and antistress proteins have all been detected in patients 
with myocarditis (Neumann et al., 1994; Pankuweit et al., 1997). Furthermore, autoimmunity 
is considered the main pathogenetic mechanism underlying eosinophilic, giant-cell and 
granulomatous myocarditis (Cihakova et al., 2008), as well as myocarditis associated with 
connective tissue diseases, peripartum cardiomyopathy (Ansari et al., 2002) or heart 
transplant, in which immunosuppression has been proven effective. 
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Immunosuppression is clearly recommended essentially for the treatment of eosinophilic, 
granulomatous, giant-cell myocarditis and lymphocytic myocarditis associated with 
connective tissue diseases or with the rejection of a transplanted heart. With regard to 
idiopathic lymphocytic myocarditis, beyond acute phase where a spontaneous resolution 
has been reported in up to 40% of the cases, many patients with idiopathic myocarditis and 
chronic heart failure are likely to benefit from immunosuppression. An up-regulation of 
HLA antigens in the myocardial tissue of patients with lymphocytic myocarditis has been 
proposed as a marker of susceptibility to beneficial effects of immunosuppression (Wojnicz 
et al., 2001). Recently the data from a randomized double-blind, placebo-controlled study 
designed to evaluate the efficacy of immunosuppression in virus-negative inflammatory 
cardiomyopathy have been reported (Frustaci et al., 2009). Eighty-five patients with 
myocarditis and chronic (>6 months) heart failure unresponsive to conventional therapy 
and no evidence of myocardial viral genomes were randomized to receive either prednisone 
and azathioprine (43 patients, Group 1) or placebo (42 patients, Group 2) in addition to 
conventional therapy for heart failure. Primary outcome was the 6 months improvement in 
left-ventricular function. Group 1 showed a significant improvement of left-ventricular 
ejection fraction and a significant decrease in left-ventricular dimensions and volumes 
compared with baseline. None of Group 2 patients showed improvement of ejection 
fraction, that significantly worsened compared with baseline. No major adverse reaction 
was registered as a result of immunosuppression. These data confirmed the efficacy of 
immunosuppression in virus-negative inflammatory cardiomyopathy. Lack of response in 
12% of cases suggested the presence of not screened viruses or mechanisms of damage and 
inflammation not susceptible to immunosuppression. Antiviral therapy is a logical strategy 
advocated for the treatment of myocarditis in patients with evidence of viral presence in 
myocardial tissue. In a small phase II study 22 patients with myocarditis and biopsy-proven 
viral persistence (15 enteroviral and 7 adenoviral) were treated with interferon-beta 18x106 
IU/week for 24 weeks. Interferon-b treatment resulted in complete elimination of both 
enteroviral and adenoviral genomes and hemodynamic improvement, as shown by 
improvement of EF and amelioration of heart failure symptoms. Importantly, treatment 
with interferon-beta was safe and well-tolerated, with no adverse cardiac effects, and flu-
like side effects could be efficiently eliminated by non-steroidal anti-inflammatory drugs 
(Kuhl et al., 2003). After these encouraging results, a prospective placebo-controlled 
randomized multicenter study, the Betaferon® in Chronic Viral Cardiomyopathy (BICC) 
trial, was initiated in 2002 and presented at the 2008 American Heart Association scientific 
sessions. The primary endpoint was virus elimination or reduction of virus load. At 24-week 
follow-up, compared to placebo, virus elimination and/or viral load reduction were 
significantly higher in the interferon group. Moreover, interferon-beta showed a good safety 
profile and was associated with beneficial effects on clinical secondary endpoints, such as 
NYHA functional class and quality of life, as assessed by Minnesota questionnaire, although 
echocardiographic and hemodynamic parameters were not statistically significantly 
different. This interesting phase II study showed proof of concept for targeted therapy based 
on molecular diagnosis in inflammatory cardiomyopathy. Future directions in the field of 
antiviral therapy include preventing direct viral damage and inhibition of viral proliferation 
by preventing the interaction of viruses with their cellular receptor and their consequent 
signalling amplification systems, such as the tyrosine kinase p56lck, phosphatase CD45 and 
downstream ERK1/2 (Liu et al., 2000). Therefore, additional research is required to further 
understand the mechanisms of viral heart disease and consequently identify new potential 
targets for therapy.  
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No specific trial or data from single-center studies on the treatment of myocarditis 
presenting with ventricular arrhythmias are currently available in literature. In patients with 
acute myocarditis, therapy for arrhythmias is essentially supportive, since arrhythmias 
usually resolve after the acute phase of the disease, which can last several weeks, together 
with the resoluton of the inflammatory process. Even in chronic myocarditis, management 
of ventricular arrhythmias is currently confined to antiarrhythmic drug therapy, with 
limited efficacy, and to implantable cardioverter-defibrillator for higher-risk patients, 
including those with hemodynamically unstable ventricular tachycardias (Zipes et al., 2006) 
and those with aborted sudden death. Radiofrequency catheter ablation has been 
demonstrated to be effective in reducing ventricular tachycardia occurrence in patients with 
Chagas cardiomyopathy and sarcoidosis. Regarding ventricular arrhythmias in patients 
with lymphocytic myocarditis, isolated reports suggest that RFCA may be effective, 
(Chauhan et al., 2008; Hama et al. 2009; Kettering et al., 2009; Zeppenfeld et al., 2007) but its 
safety and long-term efficacy in this setting is unclear. In our Institution we documented the 
safety and efficacy of RFCA in a series of consecutive patients with chronic active 
myocarditis presenting with drug-refractory ventricular tachycardias. We enrolled 20 pts 
with biopsy-proven myocarditis and drug-refractory ventricular tachycardia including 5 pts 
presenting with electrical storm. All patients underwent endocardial RFCA with an 
irrigation catheter, using contact electroanatomical mapping. Recurrence of sustained 
ventricular tachycardia after endocardial RFCA was treated with additional epicardial 
RFCA. Endocardial RFCA was acutely successful in 14 pts (70%), while in the remaining 6 
pts (30%) clinical ventricular tachycardia was successfully ablated by epicardial RFCA thus 
demonstrating that in patients with myocarditis, RFCA of drug-refractory ventricular 
tachycardia is feasible, safe and effective and that epicardial RFCA should be considered as 
an important therapeutic option to increase success rate (Pieroni and colleagues in press). 
6. Conclusion 
Myocarditis represents a frequent but often underestimated cause of life-threatening 
ventricular arrhyhmias and sudden arrhythmic death and therefore should be always 
suspected in these clinical settings. The recognition of myocarditis as the cuase of 
ventricular arrhythmias may have dramatic implications on treatment and prognosis. 
Imaging techniques such as CMR have improved our ability to recognize myocardial 
inflammatory damage, and increased the awareness of the disease among physicians. 
Nevertheless EMB still represents the gold standard for the diagnosis of myocarditis as 
offers a immunohistological and virological characterization of thr inflammatoty process 
that may influence the treatment. Electroanatomic mapping-guided EMB represents a new 
important technique that allows increasing diagnostic sensitivity and minimizing the 
sampling error in patients with myocarditis presenting with arrhythmias. In the next future 
3D-EAM-guide EMB will also represent an important research tool in the study of 
channellopathies and other genetically determined arrhythmic syndromes. 
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